iALS-1
ORIONi001-A
General
Cell Line |
|
| hPSCreg name | ORIONi001-A |
| Cite as: | ORIONi001-A (RRID:CVCL_ZE49) |
| Alternative name(s) |
iALS-1
|
| Cell line type | Human induced pluripotent stem cell (hiPSC) |
| Similar lines |
SAPi004-A (ALS III, TDP43-A382T/A382T, ALS III-TDP43-A382T/A382T) Donor diseases: Amyotrophic lateral sclerosis HIHDNDi001-A (A30P-3, SNCA3, Tue_020_A) Donor's gene variants: SNCA, SNCA, SNCA Donor diseases: autosomal dominant Parkinson disease 1 HIHDNDi001-B (A30P-4, SNCA4, Tue_020_B) Donor's gene variants: SNCA, SNCA, SNCA Donor diseases: autosomal dominant Parkinson disease 1 |
| Last update | 14th April 2022 |
| Notes | iALS-1 is a iPSc cell line generated from patient with sporadic form of ALS with a non-viral, polycistronic, synthetic RNA technology. |
| User feedback | |
Provider |
|
| Generator | Biomedical center Martin, Jessenius Faculty of Medicine in Martin, COMENIUS UNIVERSITY IN BRATISLAVA (ORION) |
| Owner | Biomedical center Martin, Jessenius Faculty of Medicine in Martin, COMENIUS UNIVERSITY IN BRATISLAVA (ORION) |
| Distributors | |
| Derivation country | Slovakia |
External Databases |
|
| BioSamples | SAMEA7002446 |
| Cellosaurus | CVCL_ZE49 |
| Wikidata | Q98128355 |
General Information |
|
| Publications |
|
| * Is the cell line readily obtainable for third parties? |
Yes Research use: allowed
Clinical use: not allowed
Commercial use: not allowed
|
Donor Information
General Donor Information |
|
| Sex | male |
| Age of donor (at collection) | 55-59 |
| Ethnicity | Caucasian |
Phenotype and Disease related information (Donor) |
|
| Diseases | A disease was diagnosed.
|
| Family history | no family history of ALS exists for this patient |
| Is the medical history available upon request? | yes, it is |
| Is clinical information available? | yes, it is |
Karyotyping (Donor) |
|
| Has the donor karyotype been analysed? |
No
|
Other Genotyping (Donor) |
|
| Is there genome-wide genotyping or functional data available? |
No
|
External Databases (Donor) |
|
| BioSamples | SAMEA7002447 |
Ethics
| Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? | Yes |
| Was the consent voluntarily given? | Yes |
| Has the donor been informed that participation will not directly influence their personal treatment? | Yes |
| Can you provide us with a copy of the Donor Information Sheet provided to the donor? | Yes |
| Do you (Depositor/Provider) hold the original Donor Consent Form? | Yes |
| Alternatives to consent are available? | No |
| Is there other documentation provided to the donor for consenting purposes? | No |
| Confirm that consent was obtained by a qualified professional | Yes |
| Has the donor agreed to be re-contacted? | Unknown |
| Has the donor been informed about how her/his data will be protected? | Yes |
| Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. | pseudonymised |
| Does consent explicitly allow the derivation of pluripotent stem cells? | Yes |
| Does consent pertain to a specific research project? | No |
| Does consent permit unforeseen future research, without further consent? | Yes |
| Does the consent permit uses of donated embryo/tissue or derived cell line intended for clinical treatment or human applications? | No |
| Does consent expressly prevent development of commercial products? | No |
| Does consent expressly prevent financial gain from any use of the donated embryo/tissue, including any product made from it? | No |
| Does consent expressly permit storage of donated embryo/tissue for an unlimited time? | Yes |
| Does consent expressly permit storage of cells derived from the donated embryo/tissue for an unlimited time? | Yes |
| Does consent prevent the DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No |
| Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No |
Does consent permit research by | |
| an academic institution? | Yes |
| a public organisation? | Yes |
| a non-profit company? | Yes |
| a for-profit corporation? | No |
| Does consent expressly permit collection of genetic information? | Yes |
| Does consent expressly permit storage of genetic information? | Yes |
| Does consent prevent dissemination of genetic information? | No |
| Has the donor been informed that their donated biosample or derived cells may be tested for the presence of microbiological agents / pathogens? | No |
| Has the donor consented to receive information discovered during use of donated embryo/tissue that has significant health implications for the donor? | No |
| How may genetic information associated with the cell line be accessed? | Controlled Access |
| Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? | No |
| Does the consent anticipate that the donor will be notified of results or outcomes of any research involving the donated samples or derived cells? | No |
| Does the consent permit the donor, upon withdrawal of consent, to stop the use of the derived cell line(s) that have already been created from donated samples? | No |
| Does the consent permit the donor, upon withdrawal of consent, to stop delivery or use of information and data about the donor? | No |
| Does consent permit access to medical records of the donor? | Yes |
| Please describe how access is provided: | Medical records will be accessible via medical doctor that was in charge for treating the patient |
| Does consent permit access to any other source of information about the clinical treatment or health of the donor? | Yes |
| Contact data, institution, or website: | Vladimir Nosal, MD, PhD, from Martin University Hospital, Slovakia |
| Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? | Yes |
| Name of accrediting authority involved? | Ethic committee of Jessenius Faculty of Medicine in Martin, Comenius Univeristy in Bratislava, Slovak Republic |
| Approval number | EK 1856/2016 |
| Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the PROPOSED PROJECT, involving use of donated embryo/tissue or derived cells? | Yes |
| Name of accrediting authority involved? | Ethic committee of Jessenius Faculty of Medicine in Martin, Comenius Univeristy in Bratislava, Slovak Republic |
| Approval number | EK 1856/2016 |
| Do you have obligations to third parties in regard to the use of the cell line? | No |
| Are you aware of any further constraints on the use of the donated embryo/tissue or derived cells? | No |
| Is there an MTA available for the cell line? | No |
| For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? | MERCK MILLIPORE https://www.merckmillipore.com/SK/sk/product/Simplicon-RNA-Reprogramming-Kit-OKSG,MM_NF-SCR550?ReferrerURL=https%3A%2F%2Fwww.google.com%2F&bd=1 |
| Are you aware of any constraints on the use or distribution of the cell line from the owner or any parties identified in the query above? | No |
hIPSC Derivation
General |
|
| Source cell type | |
| Source cell origin |
A zone of skin that is part of a lower leg [Automatically generated definition].
Synonyms
|
| Source cell type (free text) | fibroblasts isolated with explant method from skin from lower leg |
| Age of donor (at collection) | 55-59 |
| Collected in | 2017 |
| Passage number reprogrammed | P7 |
Reprogramming method |
|
| Vector type | Non-integrating |
| Vector | Simplicon™ RNA Reprogramming, single, polycistronic, synthetic, self-replicating RNA strand (contains OKS-iG; Oct4, Klf4, Sox2 and Glis1) |
| Genes | |
| Is reprogramming vector detectable? |
Unknown |
| Notes on reprogramming vector detection | According to manufacturer, |
Vector free reprogramming |
|
| Type of used vector free reprogramming factor(s) |
None
|
Other |
|
| Selection criteria for clones | morphology and expression of stem cell markers |
| Derived under xeno-free conditions |
No |
| Derived under GMP? |
No |
| Available as clinical grade? |
No |
Culture Conditions
| Surface coating | iPSc isolation started with MEFs (mouse embryonic fibroblasts), then we adopted iPSc to feeder-free conditions and used Matrigel and Vitronectin coating |
| Feeder cells |
CF-1 MEFs, EmbryoMax® Primary Mouse Embryonic Fibroblast, PMEF, Strain CF1, Mitomycin C Treated, Passage 3 Cellfinder Ont Id: EFO_0004040 |
| Passage method | Mechanically |
| O2 Concentration | 20 % |
| CO2 Concentration | 5 % |
| Medium | mTeSR™ 1 |
| Has Rock inhibitor (Y27632) been used at passage previously with this cell line? | No |
| Has Rock inhibitor (Y27632) been used at cryo previously with this cell line? | No |
| Has Rock inhibitor (Y27632) been used at thaw previously with this cell line? | No |
Characterisation
Analysis of Undifferentiated Cells
| Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
| NANOG |
Yes |
|
|
|||
| SOX2 |
Yes |
|
||||
| POU5F1 (OCT-4) |
Yes |
|
||||
| c Myc |
Yes |
|
||||
| Alkaline Phosphatase |
Yes |
|
Score:
| Marker | Present | Absent |
| mCpG | ||
| OCT4 |
Differentiation Potency
In vivo teratoma
In vitro directed differentiation
| Marker | Expressed |
| alpha smooth muscle actin |
Yes |
Protocol or reference
In vitro spontaneous differentiation
In vitro directed differentiation
| Marker | Expressed |
| Class III β-tubulin |
Yes |
Genotyping
Karyotyping (Cell Line) |
|
| Has the cell line karyotype been analysed? |
Yes
|
Other Genotyping (Cell Line) |
|
Login to share your feedback, experiences or results with the research community.